The stock also popped after CNBC’s Jim Cramer shared his outlook for the year ahead in the budding cannabis industry saying he expected “marijuana-adjacent” biotechnology companies to start getting more credit from investors for their cannabis-influenced businesses.
Zynerba’s stock climbed 25.2% to close at $4.81 Tuesday and continued the ascent Wednesday, adding another 4.8% to $5.04 in pre-market action.
“These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body,” Cramer explained.
“As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but